equipramox vet. 19.5 mg/g + 121.7 mg/g oraaligeeli
continental farmaceutica - moxidectinum,praziquantelum - oraaligeeli - 19.5 mg/g + 121.7 mg/g - moksidektiini, yhdistelmävalmisteet
equimoxectin vet. 18.92 mg/g oraaligeeli
continental farmaceutica - moxidectinum - oraaligeeli - 18.92 mg/g - moksidektiini
cortivent 50 mikrog/annos inhalaatioaerosoli
schering oy - budesonidum - inhalaatioaerosoli - 50 mikrog/annos - budesonidi
cortivent 200 mikrog/annos inhalaatiosumute, suspensio
oy leiras finland ab - budesonidum - inhalaatiosumute, suspensio - 200 mikrog/annos - budesonidi
cortivent 100 mikrog/annos inhalaatiosumute, suspensio
oy leiras finland ab - budesonidum - inhalaatiosumute, suspensio - 100 mikrog/annos - budesonidi
efmody
diurnal europe b.v. - hydrokortisoni - adrenal hyperplasia, congenital - kortikosteroidit systeemiseen käyttöön - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.
cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - hemostaatit - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.